Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report.

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is the first-line strategy for patients with non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations. Acquired resistance to EGFR-TKIs is inevitable in patients receiving EGFR-TKI therapy. Treatment with bevacizumab can induce a marked improvement in the overall and progression-free survival of patients with NSCLC; however, the effect of bevacizumab on TKI resistance in patients with NSCLC with an activating EGFR mutation is largely unknown. The present study reports the case of a patient with advanced, metastatic lung adenocarcinoma harboring 19 Del mutations, and who developed resistance to afatinib. The addition of bevacizumab to afatinib treatment was shown to overcome the acquired TKI resistance in the patient, as well as to promote an improved outcome for her brain metastases.

False-positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography in a patient with metallic implants following chondrosarcoma resection.

Positron emission tomography (PET) with fluorine-18-labeled fluorodeoxyglucose (18F-FDG) has been used for the staging and evaluation of recurrence in cancer patients. We herein report a false-positive result of 18F-FDG PET/computed tomography (CT) scan in a patient following chondrosarcoma resection and metallic implanting. A 35-year-old male patient with chondrosarcoma of the left iliac bone underwent radical resection, metal brace implanting and radiotherapy. A high uptake of 18F-FDG was observed in the metallic implants and adjacent tissue during PET/CT scanning in the 5th year of follow-up. Tissue biopsy and follow-up examination identified no tumor recurrence or infection at these sites, suggesting that the results of 18F-FDG PET/CT must be interpreted with caution in cancer patients with metallic implants.